Head-to-head · WeighScore
Kin Meds vs Sesame Care
By GLP-1 ScorecardUpdated
Score comparison
Sesame Care has the higher recorded score — 87.8/100 to 69.1/100.
Sesame Care grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Choose a provider for Wegovy, Zepbound and oral GLP-1 options through Sesame; care and medication are billed separately, and the annual care headline needs comparison with the shorter plan.
Before you choose
Before comparing the headline prices, the Kin Meds review and the Sesame Care review set out what each semaglutide figure in the table below covers, including whether the medication is a brand-name product billed by a pharmacy. Brand-name and compounded prices are different products, so set like against like before treating either one as cheaper.
If neither one fits, Kin Meds vs ShedRx and Klinic vs Sesame Care compare each of them with another graded program, and the list of alternatives to Kin Meds ranks the programs closest to Kin Meds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Kin Meds | Sesame Care |
|---|---|---|
| WeighScore | 69.1/100 | 87.8/100 |
| Grade | C | B+ |
| Site position | #147 | #2 |
| Semaglutide | Wegovy advertised from $149/mo; selected total unverified | Brand Wegovy pill from $149/mo at 1.5/4 mg; $299 at 9/25 mg, plus required care: from $59/mo on annual subscription or $99 every 28 days (confirm billing) |
| Tirzepatide | Zepbound advertised from $149/mo; selected total unverified | Brand Zepbound vials from $299/mo at 2.5 mg; higher doses cost more and KwikPen pages conflict, plus required care (confirm selected product and billing) |
| Coverage | Coverage not published | U.S. marketplace; provider and treatment availability varies; confirm your state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
FDAWarning letter issued to Kin Meds in February 2026. See the FDA warning-letter database.
Strengths
- Lists Wegovy and Zepbound on separate product pages
- Describes subscription cancellation through the patient account before shipment
What to consider
- The advertised starting price leaves the selected bill and insurance costs unverified
- The policy treats charged orders as final after carrier handoff
- Confirm service availability and dispensing pharmacy for your prescription
- FDA issued Kin Meds a warning letter in February 2026; the letter is public in FDA's warning-letter database
Site position #2 · B+
Strengths
- Provider choice with advertised video visits, follow-ups and continuing messaging
- Branded injection and oral options are described, subject to prescribing, dose, insurance and pharmacy availability
- Quest lab costs are included except in nine named states; alternative lab coverage requires confirmation
- The current semaglutide page explicitly distinguishes branded products from compounded semaglutide, which it says is currently unavailable
What to consider
- The $59 care headline requires an annual subscription and excludes medication; provider-specific care rates may be higher
- Ordinary care is called monthly but also billed every 28 days; longer-term savings arithmetic needs confirmation
- Program refund wording differs from newer terms describing multi-month repricing and a 48-hour renewal notice
- Drug prices depend on dose and promotion; official KwikPen and Foundayo displays contain discrepancies
- The selected clinician, medical practice and dispensing pharmacy were not established by this review
Featured provider
Sesame Care
Sesame Care scores 87.8/100 (B+). Choose a provider for Wegovy, Zepbound and oral GLP-1 options through Sesame; care and medication are billed separately, and the annual care headline needs comparison with the shorter plan.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.